Market capitalization | $851.01m |
Enterprise Value | $337.93m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.69 |
P/S ratio (TTM) P/S ratio | 6.77 |
P/B ratio (TTM) P/B ratio | 1.72 |
Revenue (TTM) Revenue | $125.71m |
EBIT (operating result TTM) EBIT | $-72.52m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
9 Analysts have issued a Immatics N.V forecast:
9 Analysts have issued a Immatics N.V forecast:
Sep '24 |
+/-
%
|
||
Revenue | 126 126 |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -61 -61 |
-
|
EBIT (Operating Income) EBIT | -73 -73 |
636%
636%
|
Net Profit | -60 -60 |
-
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its clinical pipelines include adoptive cell therapy (ACT) and TCR biscpecifics (TCER™). Its therapeutic approaches are ACTengine, Next Generation ACT, and TCER. The company was founded on March 10, 2020 and is headquartered in Tuebingen, Germany.
Head office | Netherlands |
CEO | Harpreet Singh-Jasuja |
Employees | 343 |
Founded | 2020 |
Website | www.immatics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.